Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Doxorubicin is an anthracycline and one of the more effective chemotherapy agents used in
the treatment of children, adolescents, and adults with osteosarcoma. Despite its …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among
patients with established heart failure. Despite supportive basic science studies, there are …

Cancer diagnostics and therapies have improved steadily over the last few decades,
markedly increasing life expectancy for patients at all ages. However, conventional and …

Minority and underresourced communities experience disproportionately high rates of fatal
cancer and cardiovascular disease. The intersection of these disparities within the …

The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

Cardiac side effects are a major drawback of anticancer therapies, often requiring the use of
low and less effective doses or even discontinuation of the drug. Among all the drugs known …

Drug-induced cardiotoxicity is a life-threatening side effect of doxorubicin (DOX) treatment
that impacts patient prognosis and survival. In the majority of cases, the acute clinical form …